Introduction:

Christy answers a listener question about Ozempic and other GLP-1 agonist drugs, and why we all should be extremely wary of any new diet drug being hailed as a "miracle."

Resources Mentioned

• Subscribe to the weekly newsletter, Food Psych Weekly

• Submit your questions for a chance to have them answered in the weekly newsletter

• My online course, Intuitive Eating Fundamentals

• My first book, Anti-Diet: Reclaim Your Time, Money, Well-Being, and Happiness Through Intuitive Eating

• My upcoming book, The Wellness Trap: Break Free from Diet Culture, Disinformation, and Dubious Diagnoses and Find Your True Well-Being

• The Making Peace with Food Card Deck

• Subscribe to the podcast here

• My first piece about the new class of diet drugs, from 2021

• Virginia Sole-Smith on the new AAP guidelines

• Ragen Chastain on the new AAP guidelines

• Content note: All of the links below contain weight-stigmatizing content and positive portrayals of diet drugs, so take care of yourself and maybe don’t click on anything if you’re feeling vulnerable. 

• People regain weight quickly once they stop these drugs

• More than 17 percent of patients taking this class of drug developed masses of undigested or partially digested food in their GI tracts

• Rare but serious side effects documented in clinical trials

• Reports of gallbladder disease in patients on these drugs, with higher risks for people taking these drugs for weight loss than for diabetes, and for those taking them long-term as opposed to short-term. 

• Semaglutide and tirzepatide shown to cause thyroid tumors in rodents

• Notorious diet drug Fen-Phen didn’t have a boxed warning, thanks to industry lobbying. 

• Belviq, another weight-loss drug that was pulled from the market in 2020 because of cancer risks, didn’t have one, either.

• Article about Ozempic in which almost all sources have consulted for Novo Nordisk